Kaitai Capital

Kaitai Capital, established in 2009 and headquartered in Hangzhou, China, is a prominent professional investment management organization. The firm has grown significantly to become a key player in the Chinese venture capital landscape, managing a substantial portfolio across various high-growth sectors. With a reported asset under management (AUM) exceeding 20 billion RMB, which translates to approximately $2.8 billion USD, Kaitai Capital demonstrates considerable financial capacity and influence in its target markets.

The firm primarily focuses its investment activities across three strategic domains: Life Health, Intelligent Technology, and New Consumption. Within Life Health, Kaitai Capital targets areas such as biotechnology, pharmaceuticals, medical devices, and digital health solutions. Their Intelligent Technology investments span artificial intelligence, big data, cloud computing, IoT, robotics, and advanced manufacturing. The New Consumption vertical includes brand consumption, cultural tourism, education, and digital content. Kaitai Capital adopts a "full life cycle" investment approach, indicating their willingness to engage with companies from early stages through to pre-IPO rounds.

Kaitai Capital's extensive portfolio includes over 100 investments, showcasing their active participation in the market. Their investment history features notable companies like Sinovac Biotech and WuXi AppTec, which were significant pre-IPO investments, underscoring their capability to deploy substantial capital into mature, high-potential enterprises. While they engage across the full life cycle, their track record suggests a strong emphasis on Series A, B, C, and growth equity rounds. Based on their considerable AUM and the nature of their portfolio companies, Kaitai Capital typically writes first checks ranging from approximately $5 million for early-stage Series A rounds to upwards of $50 million for more mature growth equity or pre-IPO opportunities. This range allows them to support companies from their initial scaling phases through to significant market expansion.